TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more
TuHURA Biosciences Inc (HURA) - Total Assets
Latest total assets as of September 2025: $25.70 Million USD
Based on the latest financial reports, TuHURA Biosciences Inc (HURA) holds total assets worth $25.70 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TuHURA Biosciences Inc - Total Assets Trend (2014–2025)
This chart illustrates how TuHURA Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TuHURA Biosciences Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
TuHURA Biosciences Inc's total assets of $25.70 Million consist of 98.2% current assets and 1.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 63.4% |
| Accounts Receivable | $222.70K | 1.1% |
| Inventory | $214.70K | 1.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how TuHURA Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TuHURA Biosciences Inc's current assets represent 98.2% of total assets in 2025, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 63.4% of total assets in 2025, down from 95.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 1.1% of total assets.
TuHURA Biosciences Inc Competitors by Total Assets
Key competitors of TuHURA Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TuHURA Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TuHURA Biosciences Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TuHURA Biosciences Inc is currently not profitable relative to its asset base.
TuHURA Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.40 | 0.64 | 6.50 |
| Quick Ratio | 0.40 | 0.64 | 6.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.33 Million | $ -1.95 Million | $ 14.99 Million |
TuHURA Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between TuHURA Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 2.89 |
| Asset Growth Rate (YoY) | 357.8% |
| Total Assets | $19.97 Million |
| Market Capitalization | $57.62 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values TuHURA Biosciences Inc's assets at a significant premium ( 2.89x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: TuHURA Biosciences Inc's assets grew by 357.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TuHURA Biosciences Inc (2014–2025)
The table below shows the annual total assets of TuHURA Biosciences Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $19.97 Million | +357.76% |
| 2024-06-30 | $4.36 Million | -71.30% |
| 2023-06-30 | $15.20 Million | +137.36% |
| 2022-06-30 | $6.40 Million | -52.73% |
| 2021-06-30 | $13.54 Million | +360.96% |
| 2020-06-30 | $2.94 Million | -27.23% |
| 2019-06-30 | $4.04 Million | -42.94% |
| 2018-06-30 | $7.07 Million | -10.57% |
| 2017-06-30 | $7.91 Million | +24.47% |
| 2016-06-30 | $6.36 Million | +146.79% |
| 2015-06-30 | $2.58 Million | -40.37% |
| 2014-06-30 | $4.32 Million | -- |